IVERIC bio (FRA:O2T) Net Income From Continuing Operations : €-212.59 Mil (TTM As of Mar. 2023)

View and export this data going back to 2013. Start your Free Trial

What is IVERIC bio Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. IVERIC bio's net income from continuing operations for the three months ended in Mar. 2023 was €-67.46 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2023 was €-212.59 Mil.

IVERIC bio Net Income From Continuing Operations Historical Data

The historical data trend for IVERIC bio's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IVERIC bio Net Income From Continuing Operations Chart

IVERIC bio Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Net Income From Continuing Operations

Get a 7-Day Free Trial

55.45

-52.97

-69.50

-101.35

-174.84

IVERIC bio Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Net Income From Continuing Operations	Get a 7-Day Free Trial															-31.36	-46.60	-42.78	-55.75	-67.46

IVERIC bio Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-212.59 Mil.

IVERIC bio (FRA:O2T) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IVERIC bio Inc (FRA:O2T) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

8 Sylvan Way, Parsippany, New Jersey, USA, 07054

Website

https://www.ivericbio.com

IVERIC bio Inc is a biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The company is developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases, or IRDs.

IVERIC bio (FRA:O2T) Headlines

No Headlines